<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00137787</url>
  </required_header>
  <id_info>
    <org_study_id>C-SHOT 0402</org_study_id>
    <nct_id>NCT00137787</nct_id>
  </id_info>
  <brief_title>Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases</brief_title>
  <official_title>Randomized Controlled Trial Comparing Ciprofloxacin With Cefepime in Febrile Neutropenic Patients With Hematologic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Supporting Hematology-Oncology Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Supporting Hematology-Oncology Trials</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as
      cefepime for the initial treatment of febrile neutropenia developed in patients with
      hematologic diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infectious complications during neutropenic periods are major causes of morbidity and
      mortality especially for patients with hematological diseases, and prompt initiation of
      antibiotic therapy is warranted for those who develop febrile neutropenia. As for initial
      therapeutic agents, beta-lactam antibiotics, i.e., third- or fourth-generation cephalosporins
      and carbapenems have been used frequently because of their strong and broad-spectrum of
      action. However, under these conditions, development of resistance mediated by a
      beta-lactamase is concerned, and there is a need for alternative non-beta-lactam antibiotics
      for this indication. Ciprofloxacin is a potent agent covering against wide range of strains
      including Pseudomonas aeruginosa, and expected as a potential candidate. We have therefore
      planned a prospective randomized controlled trial designed to compare intravenous
      ciprofloxacin with cefepime for febrile neutropenic patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2005</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment efficacy</measure>
    <time_frame>At 7 days after initiating therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment efficacy</measure>
    <time_frame>At 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>During the follow-up period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ciprofloxacin</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefepime</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hematologic disease

          -  Ages between 15 and 79 years

          -  Axillary temperature of 38.0 C or greater on one occasion or of 37.5 to 37.9 C lasting
             for more than 1 hour

          -  Absolute neutrophil count of less than 500/microL

          -  T-Bil level less than 2.0 times the upper limit of normal

          -  Cre level less than 1.5 times the upper limit of normal

          -  Written informed consent

        Exclusion Criteria:

          -  Past history of allergic reaction to the study drug

          -  Positive for HIV antibody

          -  Pregnant or lactating women

          -  Family history of auditory disturbance

          -  Having received systemic antibacterial therapy within 14 days

          -  Receiving systemic antifungal or antiviral therapy except fluconazole or acyclovir for
             cases undergoing transplantation

          -  No recovery of neutrophil count of 1,000/microL or higher from the previous febrile
             episode

          -  On treatment with ketoprofen

          -  On treatment with sodium valproate

          -  Septic shock
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshiko Atsuta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nagoya University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoshiko Atsuta, MD</last_name>
    <phone>81-52-719-1973</phone>
    <email>y-atsuta@med.nagoya-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ritsuro Suzuki, MD</last_name>
    <email>r-suzuki@med.nagoya-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nagoya University Graduate School of Medicine</name>
      <address>
        <city>Nagoya</city>
        <zip>466-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshiko Atsuta, MD</last_name>
      <phone>81-52-719-1973</phone>
      <email>y-atsuta@med.nagoya-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Tomoki Naoe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.c-shot.or.jp/</url>
    <description>The C-SHOT homepage</description>
  </link>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2005</study_first_submitted>
  <study_first_submitted_qc>August 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>November 11, 2008</last_update_submitted>
  <last_update_submitted_qc>November 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2008</last_update_posted>
  <keyword>febrile neutropenia</keyword>
  <keyword>hematologic disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

